Pathways Study News Today

New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park

A new study supports accumulating evidence that HER2-low breast cancer is a distinct biologic entity from HER2-negative breast cancer, according to researchers. A new study supports accumulating evidence that HER2-low breast cancer is a distinct biologic entity from HER2-negative breast cancer.

A Kaiser Permanente study provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol?

A multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center and Kaiser Permanente Northern California have identified the first pharmacogenomic marker for anthracyclines and HER2-targeting drugs, two commonly used breast cancer chemotherapies.

Newly discovered genetic marker identifies patients who will best respond to specific chemotherapies.

BUFFALO, N.Y. (PRWEB) March 23, 2022 -- BUFFALO, N.Y. — A multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center and Kaiser

Vertebral fractures were more often cancer-related in women with initial stage III or IV breast cancer.

Buffalo, N.Y. (PRWEB) June 04, 2021 -- The joint Roswell Park Comprehensive Cancer Center/Kaiser Permanente Northern California team behind a new study to be